JUMPCAN(SH:600566)2021-04-16 16:00Financial Performance - The company's operating revenue for 2020 was approximately ¥6.16 billion, a decrease of 11.17% compared to ¥6.94 billion in 2019[17]. - The net profit attributable to shareholders for 2020 was approximately ¥1.28 billion, down 21.30% from ¥1.62 billion in 2019[17]. - The net cash flow from operating activities was approximately ¥1.78 billion, a decrease of 17.04% compared to ¥2.15 billion in 2019[17]. - The total assets at the end of 2020 were approximately ¥10.52 billion, an increase of 21.36% from ¥8.66 billion at the end of 2019[17]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥7.76 billion, up 27.17% from ¥6.10 billion at the end of 2019[17]. - The basic earnings per share for 2020 were ¥1.53, a decrease of 23.12% compared to ¥1.99 in 2019[18]. - The weighted average return on equity for 2020 was 19.89%, a decrease of 8.54 percentage points from 28.43% in 2019[18]. Dividend Distribution - The profit distribution plan for 2020 proposes a cash dividend of 4.50 CNY per 10 shares, totaling approximately 399.72 million CNY (including tax) based on the total share capital of 888,257,259 shares as of March 31, 2021[3]. - In 2020, the company did not distribute any stock dividends, but paid a cash dividend of 4.50 RMB per 10 shares, totaling 399,715,766.55 RMB, which accounted for 31.30% of the net profit attributable to ordinary shareholders[91]. - In 2019, the company paid a cash dividend of 12.30 RMB per 10 shares, totaling 1,002,358,788.12 RMB, representing 61.76% of the net profit attributable to ordinary shareholders[91]. Audit and Compliance - The company received a standard unqualified audit report from Lixin Certified Public Accountants, ensuring the accuracy and completeness of the financial report[2]. - The company’s financial report has been declared true, accurate, and complete by the responsible persons, including the CEO and accounting head[2]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[4]. - The company has not reported any instances of more than half of the directors being unable to guarantee the authenticity and completeness of the annual report[4]. - The company has not violated decision-making procedures in providing guarantees to external parties[4]. Risks and Future Outlook - There were no significant adverse impacts on the company's production and operations during the reporting period, and potential risks to future development have been outlined[5]. - The company is subject to risks related to future development strategies and operational goals, which have been discussed in detail in the report[5]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a substantive commitment to investors[4]. - The company plans to continue its market expansion and product development strategies in the upcoming year[16]. - The company is exploring potential mergers and acquisitions to further strengthen its market presence[16]. Research and Development - The company has been focusing on research and development of new products and technologies to enhance its market position[16]. - The company aims to enhance its product portfolio through ongoing new product development and secondary development of key existing products, supporting sustainable growth[29]. - The company’s R&D expenses increased by 15.99% to CNY 243,753,085.18[33]. - The company has 811 R&D personnel, accounting for 11.71% of the total workforce[46]. - The company has a total of 13 ongoing drug development projects, showcasing its active engagement in pharmaceutical innovation[66]. Market Position and Sales - The company’s main business includes the research, production, and sales of pharmaceuticals, focusing on pediatric, digestive, and respiratory fields[26]. - The company’s revenue from pharmaceutical sales accounted for 96.42% of total revenue, while revenue from medical commercial activities was 3.58%[26]. - The company's main products, including Pudilan Oral Liquid, Rabeprazole Sodium Enteric-coated Capsules, and Pediatric Chiqiao Qingre Granules, maintain leading market shares in their respective segments[27]. - The company’s market position is supported by the increasing demand for healthcare due to an aging population and rising health awareness[26]. - The company reported a significant increase in direct labor costs by 6.48% to CNY 130,849,306.23[40]. Environmental Responsibility - The company is recognized as a key pollutant discharge unit, with ongoing monitoring and compliance with environmental regulations[121]. - The wastewater treatment facilities of Hubei Jichuan Pharmaceutical Co., Ltd. have a design capacity of 4,500 tons/day and 600 tons/day, effectively treating all production and domestic wastewater[126]. - Hubei Jichuan has implemented a comprehensive air pollution control plan, including bag dust removal and water film dust removal systems[126]. - The company has actively invested in environmental protection, aiming to be a "resource-saving and environmentally friendly" enterprise[131]. Corporate Governance - The company strictly adheres to the laws and regulations regarding corporate governance, ensuring that all shareholders can exercise their voting rights effectively[190]. - The board of directors' remuneration is approved by the shareholders' meeting, while senior management remuneration is approved by the board of directors[180]. - The company has undergone changes in its board and supervisory roles, with several independent directors being elected and appointed[182]. - The company held its first extraordinary general meeting on March 2, 2020, with 223 shareholders present, representing 70.64% of the voting rights[192]. Shareholder Information - The total number of ordinary shares increased to 888,257,259, with 814,922,174 shares being unrestricted[153]. - The company issued a total of 8,431,600 convertible bonds with a total amount of 84,316 million RMB, which began trading on November 29, 2017[135]. - The controlling shareholder is Jiangsu Jichuan Holding Group Co., Ltd., established on December 11, 2009, with no other listed companies held during the reporting period[164]. - The company anticipates a potential decline in earnings per share and return on equity due to the dilution effect from the convertible bond conversions[150].